<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633148</url>
  </required_header>
  <id_info>
    <org_study_id>UC02-PSMA-01</org_study_id>
    <secondary_id>2019-004211-32</secondary_id>
    <nct_id>NCT04633148</nct_id>
  </id_info>
  <brief_title>Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker</brief_title>
  <official_title>Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellex Patient Treatment GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PHARMALOG Institut für klinische Forschung GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellex Patient Treatment GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This dose-escalating phase I trial assesses for the first time the safety, the side effects&#xD;
      and the harmlessness, as well as the therapeutical benefit of the new study drug&#xD;
      UniCAR02-T-pPSMA in patients with progressive disease after standard systemic therapy in&#xD;
      cancers with positive PSMA marker. The UniCAR02-T-pPSMA drug is a combination of a cellular&#xD;
      component (UniCAR02-T) with a recombinant antibody derivative (TMpPSMA) which together forms&#xD;
      the active drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation follows an adaptive design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
    <description>Incidence and intensity of adverse events graded according to CTCAE V5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
    <description>DLT is defined as any adverse Event at least possible related to TMpPSMA and/or UniCAR02-T</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
    <description>The dose for which the isotonic estimate of the DLT probability is closest to the target DLT probability of 0.2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended phase 2 dose (RP2D)</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
    <description>The RP2D will be determined based on MTD, all available efficacy data, and all available safety data, including information derived from additional treatment cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
    <description>Antitumor activity of UniCAR02-T-pPSMA at any time point according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors): Complete remission (CR) and partial remission (PR), Objective response rate (ORR), Disease control rate (DCR), Best response rate, Duration of response (DOR),Progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response in prostate cancer</measure>
    <time_frame>DLT period (infusion period of TMpPSMA + 14 days or + 21 days in patients with with myelosuppression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Until fifteen years after last UniCAR02-T administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>UniCAR02-T-pPSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (Non-IMP)</intervention_name>
    <description>Intravenous infusion for 3 days</description>
    <arm_group_label>UniCAR02-T-pPSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine (Non-IMP)</intervention_name>
    <description>Intravenous infusion for 3 days</description>
    <arm_group_label>UniCAR02-T-pPSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UniCAR02-T-pPSMA</intervention_name>
    <description>Intravenous Infusion for 24 days</description>
    <arm_group_label>UniCAR02-T-pPSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UniCAR02-T (IMP)</intervention_name>
    <description>Intravenous infusion of single dose</description>
    <arm_group_label>UniCAR02-T-pPSMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age ≥ 18 years&#xD;
&#xD;
          2. PSMA expression positive cancer (i.e. urogenital tract [renal, transitional cell,&#xD;
             prostate], non-small cell lung, breast and colorectal cancer) refractory to standard&#xD;
             treatments and with no other available standard or curative treatment&#xD;
&#xD;
          3. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1 and positivity in PSMA Positron Emission Tomography (PET)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          5. Life expectancy of at least 3 months&#xD;
&#xD;
          6. Adequate renal and hepatic laboratory assessments&#xD;
&#xD;
          7. Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF)&#xD;
&#xD;
          8. Permanent venous access existing (e.g. port-system) resp. acceptance of implantation&#xD;
             of a device&#xD;
&#xD;
          9. Able to give written informed consent&#xD;
&#xD;
         10. Weight ≥ 45kg&#xD;
&#xD;
         11. Negative pregnancy; routinely using a highly effective method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system metastasis or meningeosis carcinomatosa&#xD;
&#xD;
          2. Cardiac disease: i.e. heart failure (NYHA III or IV); unstable coronary artery&#xD;
             disease, myocardial infarction or serious cardiac ventricular arrhythmias requiring&#xD;
             anti-arrhythmic therapy within the last 6 months prior to study entry&#xD;
&#xD;
          3. Patients undergoing renal dialysis&#xD;
&#xD;
          4. Pulmonary disease with clinical relevant hypoxia (need for continuous oxygen&#xD;
             inhalation)&#xD;
&#xD;
          5. Parkinson, epilepsy and stroke or presence or history of seizures, paresis, aphasia,&#xD;
             central nervous system (CNS) or intracranial hemorrhage&#xD;
&#xD;
          6. History or presence of disseminated intravascular coagulation (DIC) or thromboembolism&#xD;
&#xD;
          7. Multiple sclerosis&#xD;
&#xD;
          8. Hemolytic anemia&#xD;
&#xD;
          9. Eye diseases with neovascularization&#xD;
&#xD;
         10. Active infectious disease considered by investigator to be incompatible with protocol&#xD;
             or being contraindications for lymphodepletion therapy&#xD;
&#xD;
         11. Presence of urotoxicity from previous chemo- or radiotherapy or urinary outflow&#xD;
             obstruction&#xD;
&#xD;
         12. Vaccination with live viruses less than 2 weeks prior lymphodepletion therapy&#xD;
&#xD;
         13. Any disease requiring immunosuppressive therapy&#xD;
&#xD;
         14. Major surgery within 28 days (prior start of TMpPSMA infusion)&#xD;
&#xD;
         15. Other malignancy requiring active therapy but adjuvant endocrine therapy is allowed&#xD;
&#xD;
         16. Treatment with any investigational drug substance or experimental therapy within 4&#xD;
             weeks or 5 half-lives of the substance (whatever is shorter) prior to administration&#xD;
             of TMpPSMA&#xD;
&#xD;
         17. Prior treatment with gene therapy products&#xD;
&#xD;
         18. Use of checkpoint inhibitors within 5 half-lives of the respective substance prior to&#xD;
             administration of TMpPSMA&#xD;
&#xD;
         19. Autoimmune diseases requiring systemic steroids or other systemic immunosuppressants&#xD;
             (note that physiologic steroid replacement not exceeding 10 mg prednisolone equivalent&#xD;
             per day is allowed)&#xD;
&#xD;
         20. Psychologic disorders, drug and/or significant active alcohol abuse&#xD;
&#xD;
         21. Known history of human immunodeficiency virus (HIV) or active/chronic infection with&#xD;
             hepatitis C virus (HCV) or hepatitis B virus (HBV)&#xD;
&#xD;
         22. Presence of autoantibodies against La/SS-B or presence or history of autoimmune&#xD;
             diseases (e.g. systemic lupus erythematosus, SS/SLE overlap syndrome, subacute&#xD;
             cutaneous lupus erythematosus, neonatal lupus, primary biliary cirrhosis, Sjögren's&#xD;
             syndrome)&#xD;
&#xD;
         23. Known hypersensitivity to cellular component (UniCAR02-T) and/or targeting peptide&#xD;
             module (TMpPSMA) excipients and/or contraindication to compounds of the&#xD;
             lymphodepletion therapy (cyclophosphamide and fludarabine), and tocilizumab or&#xD;
             corticosteroids as specified in the respective IB/SmPC&#xD;
&#xD;
         24. Evidence suggesting that the patient is not likely to follow the study protocol (e.g.&#xD;
             lacking compliance)&#xD;
&#xD;
         25. Incapability of understanding purpose and possible consequences of the trial&#xD;
&#xD;
         26. Patients who should not be included according to the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Bargou, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antje Schubert, Dr.</last_name>
    <phone>+493514466450</phone>
    <phone_ext>0</phone_ext>
    <email>UC02-PSMA-01@cellex-treatment.me</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Lorkowski, Dr.</last_name>
    <phone>+493514466450</phone>
    <phone_ext>0</phone_ext>
    <email>UC02-PSMA-01@cellex-treatment.me</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Viardot, Prof.</last_name>
      <email>andreas.viardot@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Bargou, Prof.</last_name>
      <email>Bargou_R@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wermke, Dr. med</last_name>
      <email>martin.wermke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunhild von Amsberg, Prof.</last_name>
      <email>g.von-amsberg@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

